MA56391B1 - Agonistes du récepteur du peptide de type glucagon 1 - Google Patents

Agonistes du récepteur du peptide de type glucagon 1

Info

Publication number
MA56391B1
MA56391B1 MA56391A MA56391A MA56391B1 MA 56391 B1 MA56391 B1 MA 56391B1 MA 56391 A MA56391 A MA 56391A MA 56391 A MA56391 A MA 56391A MA 56391 B1 MA56391 B1 MA 56391B1
Authority
MA
Morocco
Prior art keywords
glucagon
peptide
receptor agonists
compound
formula
Prior art date
Application number
MA56391A
Other languages
English (en)
Other versions
MA56391A (fr
Inventor
Fucheng Qu
David Andrew Coates
Todd Fields
Joseph Daniel Ho
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from PCT/US2020/038617 external-priority patent/WO2020263695A1/fr
Publication of MA56391A publication Critical patent/MA56391A/fr
Publication of MA56391B1 publication Critical patent/MA56391B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dans un mode de réalisation, la présente invention concerne un composé de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci, et des procédés d'utilisation de ce composé pour le traitement du diabète sucré de type ii.
MA56391A 2019-06-28 2020-06-19 Agonistes du récepteur du peptide de type glucagon 1 MA56391B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962868117P 2019-06-28 2019-06-28
PCT/US2020/038617 WO2020263695A1 (fr) 2019-06-28 2020-06-19 Agonistes du récepteur du peptide de type glucagon 1

Publications (2)

Publication Number Publication Date
MA56391A MA56391A (fr) 2022-05-04
MA56391B1 true MA56391B1 (fr) 2023-11-30

Family

ID=80781601

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56391A MA56391B1 (fr) 2019-06-28 2020-06-19 Agonistes du récepteur du peptide de type glucagon 1

Country Status (2)

Country Link
AR (1) AR119173A1 (fr)
MA (1) MA56391B1 (fr)

Also Published As

Publication number Publication date
MA56391A (fr) 2022-05-04
AR119173A1 (es) 2021-12-01

Similar Documents

Publication Publication Date Title
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
JOP20250198A1 (ar) مركبات مساعدة مشتركة gip/glp1
PH12022552056A1 (en) Heterocyclic glp-1 agonists
CR20230066A (es) Agonistas del glp-1 heterocíclicos
PH12022550232A1 (en) Gipr-agonist compounds.
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
MA65131A1 (fr) Utilisation d'un inhibiteur d'ezh2 dans la préparation d'un médicament pour le traitement d'un lymphome à cellules t
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA58993A1 (fr) Antagoniste du récepteur crf1 pour le traitement de l'hyperplasie surrénale congénitale
MA39247A1 (fr) 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque
MX2023013717A (es) Agonistas macrociclicos del receptor del peptido-1 similar al glucagon.
EA202090392A3 (ru) Соединения-коагонисты гип и гпп-1
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
CO5150232A1 (es) METODO Y COMBINACION QUE UTILIZAN (+) NORCISAPRIDA EN COMBINACION CON INHIBIDORES DE BOMBA DE PROTONES O ANTAGONISTAS DEL RECEPTOR H[sub 2]
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
MX2025005718A (es) Agonistas del receptor del peptido-1 similar al glucagon
JOP20210329A1 (ar) مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز
MX2025015078A (es) Formulaciones de analogos peptidicos de oxintomodulina
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
Santin et al. Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions
MA56391B1 (fr) Agonistes du récepteur du peptide de type glucagon 1
AR074437A1 (es) Tratamiento para la glomerulonefritis
FR3121841B1 (fr) Traitement des hyperammoniémies